p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder.
about
Molecular substratification of bladder cancer: moving towards individualized patient managementSearch for the tumor-related proteins of transition cell carcinoma in Taiwan by proteomic analysis.Identification of methylated genes associated with aggressive bladder cancer.Expression profiling for bladder cancer: strategies to uncover prognostic factors.Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRbPredictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha.Proteome-based diagnostics and prognosis of bladder transitional cell carcinoma.Predicting survival after radical cystectomy for bladder cancer.Role of chemokine C-C motif ligand-1 in acute and chronic pulmonary inflammationsAssessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an exampleMolecular targets and targeted therapies in bladder cancer management.Strategies for molecular expression profiling in bladder cancer.Prognostic value of cell-cycle regulation biomarkers in bladder cancer.Tp53 and its potential therapeutic role as a target in bladder cancer.Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters.The molecular pathology of urological malignancies.Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy.p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.
P2860
Q26744343-55248AAB-9759-4C20-9570-E34BD7946D3BQ33231138-4EA4BE2A-68AF-4B01-9AF5-009987685775Q33680247-2D803151-B6A0-47AB-ADBE-4882F23C1BB2Q34537170-240E926E-133F-4AE7-B42B-BE0BDF71AB1AQ36634023-F5D55390-FB72-4FE1-B631-A722EF5A0019Q36695399-30126391-8434-47E7-98A3-829A38011A9AQ36740438-D209870B-60C9-4B9A-AED0-E3E9CF57E761Q36973777-439FB508-42E0-4250-AAF4-A1410992C74DQ37103989-7C9B7ACE-8BD2-4191-A856-0C7579CD2E87Q37146836-C810B0F0-5B51-4D29-A4E1-8B103965D4AFQ37236560-77E07B04-D999-4D37-9D52-2B51F792ED25Q37336643-640B8F27-0026-4E4E-8485-ECED7D060C49Q37649553-4A652701-9F66-4CC8-82BC-8187409EB274Q38049692-893306D9-5E42-4C75-89F6-5FB56752A60FQ38436074-CD64886C-3570-4B06-8852-0ED9F9FCDC78Q41173941-F27EEDC3-78A6-4779-8582-33E76A7C647AQ41718644-5B5701AD-BAB0-4FE2-8088-8F68A3ABE769Q44710572-2A8F49B7-B661-49BB-B16F-701B583AC827Q48362485-86013EDE-332B-458A-B7DA-16E25A0D2AA5
P2860
p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
p53 immunohistochemistry as an ...... cell carcinoma of the bladder.
@ast
p53 immunohistochemistry as an ...... cell carcinoma of the bladder.
@en
type
label
p53 immunohistochemistry as an ...... cell carcinoma of the bladder.
@ast
p53 immunohistochemistry as an ...... cell carcinoma of the bladder.
@en
prefLabel
p53 immunohistochemistry as an ...... cell carcinoma of the bladder.
@ast
p53 immunohistochemistry as an ...... cell carcinoma of the bladder.
@en
P2093
P2860
P356
P1476
p53 immunohistochemistry as an ...... cell carcinoma of the bladder.
@en
P2093
Bokemeyer C
Hervatin C
P2860
P2888
P304
P356
10.1038/BJC.1995.41
P407
P577
1995-01-01T00:00:00Z